Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | ctDNA MRD detection in patients with NSCLC

Bruna Pellini • 5 Jun 2022
ASCO 2022
Lung Cancer Non-Small Cell Lung Cancer

Bruna Pellini, MD, Moffitt Cancer Center, Tampa, FL, reviews evidence avialble regarding circulating tumor DNA (ctDNA) minimal residual disease (MRD) of non-small cell lung cancer (NSCLC) treated with curative intent, as well as prospective studies in this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Bruna Pellini

3:44
Evaluating the use of ctDNA as a biomarker in lung cancer
Bruna Pellini • 21 Feb 2024
5:12
How can ctDNA assess MRD and profile tumor types in lung cancer?
Bruna Pellini • 21 Feb 2024
0:56
ctDNA sensitivity in early-stage disease
Bruna Pellini • 5 Jun 2022
2:06
Applications of ctDNA in oncology
Bruna Pellini • 5 Jun 2022

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals